Integrative Oncology

A CLINICAL DISCUSSION: Hormone Replacement Therapy After Breast Cancer A Multidisciplinary Case Discussion

breast cancer

A CLINICAL DISCUSSION: Hormone Replacement Therapy After Breast Cancer A Multidisciplinary Case Discussion

BY Yoon Hang Kim, MD, MPH ◆   ◆   ◆ When Standard Guidance Meets Unusual Biology HYPOTHETICAL CASE DISCUSSION For educational and clinical reasoning purposes only EXECUTIVE SUMMARY The Question at the Center of This Case A postmenopausal woman with a complex breast cancer history sits at the intersection of three competing risks: progressive

By Yoon Hang Kim MD
Evaluating Surgical and Integrative Oncology Options in Early-Stage Breast Carcinoma with Favorable Histology and Multiple Lesions

Integrative Oncology

Evaluating Surgical and Integrative Oncology Options in Early-Stage Breast Carcinoma with Favorable Histology and Multiple Lesions

A Case-Based Review of Attributable Benefit, Attributable Risk, and the Role of Integrative Strategies Alongside Definitive Treatment Yoon Hang Kim, MD, MPH  •  Board-Certified in Preventive Medicine  |  Integrative & Functional Medicine Physician Introduction When a client presents with a new diagnosis of early-stage breast carcinoma, two sets of

By Yoon Hang Kim MD
Rethinking Cancer at the Root: The Mitochondrial–Stem Cell Connection and an Orthomolecular Approach to Treatment

Integrative Oncology

Rethinking Cancer at the Root: The Mitochondrial–Stem Cell Connection and an Orthomolecular Approach to Treatment

INTEGRATIVE ONCOLOGY By Yoon Hang Kim, MD, MPH  |  Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Published by Yoon Hang Kim MD  |  Telemedicine across Iowa, Illinois, Missouri, Texas, Georgia & Florida ⚠ Medical Disclaimer This article is intended for educational purposes only and does not constitute medical advice. The

By Yoon Hang Kim MD

Integrative Oncology

Toward the Exceptional Cancer Patient - What Bernie Siegel, Viktor Frankl, Radical Remission, and How to Starve Cancer Have in Common — and Why It Matters for Optimal Outcomes

Yoon Hang “John” Kim, MD, MPH  |  www.directintegrativecare.com An Academic Perspective on Integrative Oncology Why This Synthesis Matters Patients facing a serious cancer diagnosis often arrive at a familiar crossroads. The conventional oncology team hands them a treatment plan — chemotherapy, radiation, surgery, increasingly immunotherapy and targeted agents — and the

By Yoon Hang Kim MD
Cholangiocarcinoma -A Clinical Overview: Staging, Treatment Algorithm, and an Integrative Oncology Checklist

Integrative Oncology

Cholangiocarcinoma -A Clinical Overview: Staging, Treatment Algorithm, and an Integrative Oncology Checklist

Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the epithelial lining of the biliary tree. The disease is traditionally divided by anatomic origin into three subtypes: intrahepatic (iCCA, arising from small bile ducts within the liver), perihilar (pCCA, at the hepatic duct confluence), and distal (dCCA, within the extrahepatic bile

By Yoon Hang Kim MD